沃森生物(300142.SZ)取得一項發明專利證書
格隆匯 8 月 7日丨沃森生物(300142.SZ)公佈,公司於近日收到一項由中華人民共和國國家知識產權局頒發的發明專利證書,涉一種13價肺炎球菌多糖-蛋白結合物組合物及其製備方法和應用。
該發明公開了一種13價肺炎球菌多糖-蛋白結合物組合物及其製備方法和應用。所述組合物包括13種不同的肺炎球菌多糖-蛋白結合物,其中每種肺炎球菌多糖-蛋白結合物包含來自不同肺炎球菌血清型的莢膜多糖和載體蛋白,所述莢膜多糖來源於1型、3型、4型、5型、6A型、6B型、7F型、9V型、14型、18C型、19A型、19F型和23F型肺炎球菌,載體蛋白是單體純度≥90%的TT。該發明提供的組合物經三期臨牀研究驗證在2月齡-5週歲人羣均可誘導產生血清型特異的IgG抗體,其中在主要目標人羣2-6月齡經3針基礎免疫後,所有血清型特異性IgG濃度≥0.35μg/ml的比例均≥85%,經加強免疫後比例均≥95%。
上述發明專利已應用於公司相關產品。上述專利獲得授權有利於加強對公司知識產權的保護,提高公司的核心競爭力。對公司近期生產經營和業績不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.